Dianthus Therapeutics (NASDAQ:DNTH) Earns "Buy" Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH - Free Report) in a research report released on Tuesday morning,Benzinga reports. They currently have a $40.00 target price on the stock. HC Wainwright also issued estimates for Dianthus Therapeutics' Q2 2025 earnings at ($1.01) EPS, Q3 2025 earnings at ($0.97) EPS, FY2025 earnings at ($3.78) EPS, Q1 2026 earnings at ($0.95) EPS, Q2 2026 earnings at ($1.09) EPS, Q3 2026 earnings at ($1.23) EPS, Q4 2026 earnings at ($1.26) EPS, FY2026 earnings at ($4.54) EPS, FY2027 earnings at ($4.24) EPS, FY2028 earnings at ($3.79) EPS and FY2029 earnings at ($0.56) EPS.

Several other research analysts also recently weighed in on DNTH. Wedbush reiterated an "outperform" rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Guggenheim reissued a "buy" rating and issued a $84.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $53.00.

Dianthus Therapeutics Trading Up 5.0%

Shares of NASDAQ DNTH traded up $0.94 during trading on Tuesday, reaching $19.69. The company had a trading volume of 338,777 shares, compared to its average volume of 271,018. Dianthus Therapeutics has a twelve month low of $13.37 and a twelve month high of $32.27. The stock has a 50-day moving average price of $19.40 and a two-hundred day moving average price of $22.11. The stock has a market capitalization of $633.23 million, a PE ratio of -7.88 and a beta of 1.48.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.86) by $0.04. The company had revenue of $1.16 million for the quarter, compared to analyst estimates of $0.81 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. On average, sell-side analysts predict that Dianthus Therapeutics will post -2.61 EPS for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in DNTH. Barclays PLC increased its position in Dianthus Therapeutics by 390.5% during the 3rd quarter. Barclays PLC now owns 41,684 shares of the company's stock worth $1,141,000 after purchasing an additional 33,185 shares in the last quarter. SG Americas Securities LLC increased its position in shares of Dianthus Therapeutics by 9.2% in the fourth quarter. SG Americas Securities LLC now owns 9,653 shares of the company's stock worth $210,000 after acquiring an additional 814 shares in the last quarter. KBC Group NV acquired a new stake in shares of Dianthus Therapeutics in the fourth quarter worth $35,000. R Squared Ltd purchased a new position in shares of Dianthus Therapeutics in the 4th quarter valued at $26,000. Finally, Rhumbline Advisers lifted its holdings in shares of Dianthus Therapeutics by 3.8% during the 4th quarter. Rhumbline Advisers now owns 35,933 shares of the company's stock valued at $783,000 after acquiring an additional 1,316 shares in the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.